This article is more than 5 years old. Information may no longer be current.

Ophthotech acquires Versant Ventures-backed Inception 4

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ophthotech Corp. has acquired Inception 4 Inc. and its small molecule inhibitors of HtrA1, which are under development for the treatment of a range of retinal diseases, the company announced in a press release.

Ophthotech obtained $6.1 million in cash through the acquisition of Inception 4, which is backed by Versant Ventures. In addition, Ophthotech agreed to issue approximately 5.2 million shares of Inception 4, and Versant Ventures will own approximately 12.5% of Ophthotech’s outstanding common stock shares.

“We are thrilled to welcome Versant Ventures as a major shareholder through our acquisition of Inception 4,” Ophthotech CEO Glenn P. Sblendorio said. “This HtrA1 inhibitor program aligns with our commitment to further build upon Ophthotech’s strategy to develop novel therapeutics and gene therapy treatments for retinal diseases.”

A correlation has been demonstrated between HtrA1 (high temperature requirement A serine peptidase 1 protein) and a risk for dry age-related macular degeneration in genetic linkage studies, according to the release.